Nektar Therapeutics NKTR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.2M-67.5% | $9.82M-45.0% | $17.84M+103% | $8.8M+604% | ||
| $230.64M+9.3% | $210.97M-21.4% | $268.34M-35.6% | $416.75M-41.2% | ||
| $266.27M+1.9% | $261.29M-21.0% | $330.7M-39.4% | $545.97M-31.4% | ||
| $280.41M-7.7% | $303.85M-23.7% | $398.03M-44.0% | $710.6M-36.4% | ||
| $10.77M-6.8% | $11.56M+17.4% | $9.85M-24.1% | $12.98M+33.2% | ||
| $53.54M-12.8% | $61.4M+19.8% | $51.27M-24.8% | $68.2M-19.9% | ||
| $190.57M-21.6% | $243.11M-9.0% | $267.05M-22.4% | $343.96M-21.4% | ||
| 390M+38,999,900% | 1K-94.7% | 19K0.0% | 19K0.0% | ||
| -$3.76B-4.6% | -$3.6B-3.4% | -$3.48B-8.6% | -$3.2B-13.0% | ||
| $89.83M+47.9% | $60.74M-53.6% | $130.99M-64.3% | $366.64M-46.0% | ||
| $280.41M-7.7% | $303.85M-23.7% | $398.03M-44.0% | $710.6M-36.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Nektar Therapeutics cover its short-term obligations?
- Its current ratio is 10.21 — current assets exceed current liabilities.
- Where does Nektar Therapeutics's balance sheet data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.